Up to 80% of Russians will be vaccinated against coronavirus by fall 2021, developer says
This disease will be vaccine-controlled, Director of the Gamaleya National Center of Epidemiology and Microbiology Alexander Gintsburg said
MOSCOW, December 19. /TASS/. Up to 80% of Russians are expected to be vaccinated against coronavirus by the fall of 2021, Director of the Gamaleya National Center of Epidemiology and Microbiology Alexander Gintsburg said in an interview with Rossiya 1 TV channel. If a month, and this is quite realistic for our domestic consumption, we will produce 5-6 mln doses of vaccine, then by the end of fall 2021 we should vaccinate 70-80% of our population, that is, this disease will be vaccine-controlled, he said.
Russia developing 26 vaccine options for COVID-19
Photo courtesy of TASS
MINSK, 16 December (BelTA) – Russian scientists are developing 26 vaccine options for COVID-19 at 17 research centers, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being [Rospotrebnadzor] Anna Popova said, TASS reports.
“At present Russia is developing 26 vaccine options for COVID-19 at 17 research centers,” Anna Popova said at a meeting of the chiefs of consumer safety and sanitary watchdogs of the BRICS countries.
Speaking about EpiVacCorona, a COVID-19 vaccine developed by the Novosibirsk-based State Research Center of Virology and Biotechnology VECTOR, the Rospotrebnadzor chief informed that EpiVacCorona post-registration trials on 150 volunteers older than 60 years wrap up on 16 December.
Russia has so far registered two domestic coronavirus vaccines
MOSCOW, December 16. /TASS/. Work on 26 coronavirus vaccine options is underway in Russia, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Anna Popova said at a meeting of the sanitary watchdog chiefs from BRICS countries. Work on 26 vaccine options is underway at 17 research centers, she pointed out.
Read also
Russia has so far registered two domestic coronavirus vaccines, one of which was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology and the other one by the State Research Center of Virology and Biotechnology Vector. A third vaccine, developed by the Russian Academy of Sciences’ Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, may be registered in the near future.